Fig. 3

a, b Estimated endpoint means and effect sizes for the depressed mood item in placebo-treated subjects and in duloxetine-treated subjects with or without adverse events a only counting initial adverse events (reported during week 1–2 and b counting any adverse event throughout the trial. Placebo: n = 998; duloxetine without early adverse events: n = 713; duloxetine with early adverse events: n = 1 029; duloxetine without any adverse event throughout the trial: n = 449; duloxetine with any adverse event throughout the trial: n = 1 293. Effect sizes: a duloxetine with adverse events vs placebo: 0.46; duloxetine without adverse events vs placebo: 0.34, duloxetine with adverse events vs duloxetine without adverse events: 0.12 b duloxetine with adverse events vs placebo: 0.44: duloxetine without adverse events vs placebo: 0.36; duloxetine with adverse events vs duloxetine without adverse events: 0.12. *p = 0.02 (a), p = 0.04 (b); ***p < 0.001